Article

Therapeutic Nucleus-Access BNCT Drug Combined CD47-Targeting Gene Editing in Glioblastoma

2021-11-15

Abstract excerpt

<title>Abstract</title> <p>Glioblastoma is the most common brain primary malignant tumor with the highest mortality. Boron neutron capture therapy (BNCT) can efficiently kill cancer cells on the cellular scale, with high accuracy, short course and low side-effects, which is regarded as the most promising therapy for malignant brain tumors like glioma. As the keypoint of BNCT, all boron delivery agents currently i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 979c40ea-0fad-5898-8e4c-1afffb37ecfa
DOI: 10.21203/rs.3.rs-1036834/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Nucleus-Access BNCT Drug Combined CD47-Targeting Gene Editing in GlioblastomaDOI 10.21203/rs.3.rs-1036834/v1Read

Catalytic modulation of the tumor microenvironment using cascade enzymes for synergistic boron neutron capture therapy in the treatment of gliomasSemantic proximity Read

Human glioblastoma-derived cell membrane nanovesicles: a novel, cell-specific strategy for boron neutron capture therapy of brain tumorsSemantic proximity Read

Clinical Viability of Boron Neutron Capture Therapy for Personalized Radiation TreatmentSemantic proximity Read

Bone marrow-derived macrophages loaded with boron carbide nanoparticles as selective boron carriers for crossing the blood-brain barrier toward the glioma microenvironment for boron neutron capture therapySemantic proximity Read

Overcoming standard-of-care resistance in glioblastoma using nanoparticle-based drug delivery targeting the autophagy pathwaySemantic proximity Read

Boron Theranostic Nanoplatform Utilizing a GO@Carborane@Au Hybrid Framework for Targeted DeliverySemantic proximity Read

Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1R132H mutation-negative glioblastoma.Semantic proximity Read

Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiformeSemantic proximity Read

Translational Evaluation of a Dodecaborated Albumin Conjugate With Maleimide as a Boron Delivery System for a Neutron Capture Reaction to an F98 Rat Glioma ModelSemantic proximity Read

Therapeutic targeting of chronic lymphocytic leukemia by silver nanoparticlesSemantic proximity Read

Harnessing the Cross-talk between Tumor Cells and Tumor-associated Macrophages with a Nano-drug for modulation of Glioblastoma Immune MicroenvironmentSemantic proximity Read

Systemic delivery of a CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapySemantic proximity Read